InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (2 ops.)
Browse the detailed record of transactions filed by Alexandre Fraichard, Chief Executive Officer. Officer active across 1 companies, notably GENOWAY. Aggregated, 6 disclosures have been recorded. Total volume traded: €291k. The latest transaction was disclosed on 31 March 2025 — Acquisition. Regulator: AMF. All data is accessible without signup.
Declarations6 total
€34,68711,299 shares@ €3.06990.10% mcap11.9% of flow
ActionEuronext Growth Paris
2025DD1029025·
Ideal exit: 26 Dec 2025 (T+270)
€38,05412,500 shares@ €3.04430.11% mcap13.1% of flow
ActionEuronext Paris
2025DD1018016·
Ideal exit: 28 Oct 2025 (T+270)
€62,42818,123 shares@ €3.44470.18% mcap21.4% of flow
ActionEuronext Paris
2022DD841055·
Ideal exit: 5 Feb 2023 (T+270)
€65,64718,877 shares@ €3.47760.19% mcap22.5% of flow
ActionEuronext Paris
2022DD837134·
Ideal exit: 18 Jan 2023 (T+270)
€85,03217,613 shares@ €4.82780.25% mcap29.2% of flow
ActionEuronext Paris
2021DD799195·
€5,5061,147 shares@ €4.800.016% mcap1.9% of flow
ActionEuronext Paris
2021DD798221·
6 of 6 declarations
About Alexandre Fraichard
Alexandre Fraichard is the Chief Executive Officer and co-founder of genOway, a Lyon-based biotechnology company specializing in the design and commercialization of genetically modified preclinical models for pharmaceutical and academic research. Founded in 1999, genOway has built its business around highly predictive mouse, rat, and cellular models, with a strong focus on translational research, immuno-oncology, and immunotherapy. Public company materials identify Fraichard as a central member of the current management team and one of the key figures behind the company’s long-term development. In his executive role, he has overseen genOway’s expansion from a founder-led biotechnology venture into a recognized European player in customized preclinical solutions. The company’s public communications portray him as a leader focused on commercial scaling, industrial structuring, and international growth. In 2024, genOway unveiled its Route 50+ strategic plan, and Fraichard publicly framed the initiative around ambitious growth, operational strengthening, and value creation. He has also been associated with the company’s low-carbon program launched in 2021, which targets a 6% annual reduction in greenhouse gas emissions between 2022 and 2027; in that context, he emphasized that economic performance and environmental responsibility should advance together. Fraichard’s profile reflects long-term entrepreneurial leadership. He has remained closely involved with genOway since its creation, helping shape its strategic direction, scientific positioning, and market credibility. Public sources consistently present him as a founder-operator with experience at the intersection of biotechnology, business development, and listed-company governance. His reputation is tied to building a specialized life-science platform that serves biopharmaceutical companies and academic institutions, while maintaining a disciplined focus on innovation, execution, and sustainable growth.
